Journal
NATURE METHODS
Volume 10, Issue 1, Pages 28-34Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nmeth.2309
Keywords
-
Categories
Funding
- Broad Institute of MIT and Harvard
- US National Cancer Institute part of the Clinical Proteomics Tumor Analysis Consortium initiative [U24CA160034]
- National Heart, Lung, and Blood Institute [HHSN268201000033C, R01HL096738]
- Entertainment Industry Foundation
- Komen Foundation
- NATIONAL CANCER INSTITUTE [U24CA160034] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096738] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Targeted mass spectrometry (MS) is becoming widely used in academia and in pharmaceutical and biotechnology industries for sensitive and quantitative detection of proteins, peptides and post-translational modifications. Here we describe the increasing importance of targeted MS technologies in clinical proteomics and the potential key roles these techniques will have in bridging biomedical discovery and clinical implementation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
